http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yanagisawa, Y.,Suetomi, Y.,Piao, R.,Yamagishi, K.,Takao, T.,Hamada, M.,Saito, K.,Ohki, K.,Yamaguchi, T.,Nagaishi, T.,Kitaguchi, H.,Ueda, H.,Shimoyama, J.,Ishii, Y.,Tomita, M.,Maeda, H. The Korea Institute of Applied Superconductivity a 2018 초전도와 저온공학 Vol.20 No.2
The present article briefly overviews the plan for a new project on joint technology for HTS wires/cables and describes the development plan for the world's highest field NMR magnet, which is a major development item in the project. For full-fledged social implementation of superconducting devices, high temperature superconducting (HTS) wire is a key technology since they can be cooled by liquid nitrogen and they can generate a super-high magnetic field of >>24 T at liquid helium temperatures. However, one of the major drawbacks of the HTS wires is their availability only in short lengths of a single piece of wire. This necessitates a number of joints being installed in superconducting devices, resulting in a difficult manufacturing process and a large joint resistance. In Japan, a large-scale project has commenced, including two technical demonstration items: (i) Development of superconducting joints between HTS wires, which are used in the world's highest field 1.3 GHz (30.5 T) NMR magnet in persistent current mode; the joints performance is evaluated based on NMR spectra for proteins. (ii) Development of ultra-low resistive joints between DC superconducting feeder cables for railway systems. The project starts a new initiative of next generation super-high field NMR development as well as that of realization of better superconducting power cables.
Makoto Nishio,김동완,Yi-Long Wu,Kazuhiko Nakagawa,Benjamin J. Solomon,Alice T. Shaw,Satoshi Hashigaki,Emiko Ohki,Tiziana Usari,Jolanda Paolini,Anna Polli,Keith D. Wilner,Tony Mok 대한암학회 2018 Cancer Research and Treatment Vol.50 No.3
Purpose Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. Materials and Methods This analysis evaluated previously treated and untreated patients in two randomized, openlabel phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively. Results In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade) with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. Conclusion These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.
Low-noise inducing Rx for human body communication
Oh, K.-I.,Kang, T.W.,Kim, S.E.,Park, H.-I.,Lim, I.G.,Kang, S.W. IET 2016 Electronics letters Vol.52 No.21
<P>A low-noise inducing receiver (Rx) for human body communication is proposed. By minimising switching noise from the digital circuit of the Rx and coupling of the signal to the Rx ground, stable and reliable communication was accomplished even when the transmitter (Tx) and the Rx were attached to the human body. A prototype Tx and Rx were implemented with a PCB size of 5 x 6 cm. They were tested with this low-noise inducing Rx design and accomplished a data rate of 1 Mbits/s without any cyclic redundancy check (CRC) error.</P>